Rockland Trust’s Ocular Therapeutix OCUL Stock Holding History

Rockland Trust’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	-$1K	–	244
2018 Q4	$1K	Buy	+100	New	+$551	﹤0.01%	242

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Rockland Trust's OCUL Position: Q1 2019 in Review

Rockland Trust sold out of Ocular Therapeutix (OCUL) in Q1 2019, closing a stake of 100 shares — an estimated $1K sold.

Rockland Trust first reported a position in OCUL in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 68 funds tracked by Wall St. Rank hold OCUL as of Q1 2019.

Rockland Trust reported no remaining Ocular Therapeutix position as of Q1 2019 after selling out during the quarter.
Rockland Trust sold 100 Ocular Therapeutix shares in Q1 2019, an estimated $1K.
Rockland Trust first reported a position in Ocular Therapeutix in Q4 2018 and held it in 1 quarter.
Rockland Trust's Ocular Therapeutix position peaked at $1K in Q4 2018.
68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2019.

Based on Rockland Trust's 13F filing for Q1 2019, filed 8 Apr 2019.